Triggering receptor expressed on myeloid cells 1 (TREM1) is an immunoglobulin (Ig) superfamily transmembrane protein that, in humans, is encoded by the TREM1 gene.

2023年2月7日 · Triggering receptors expressed on myeloid cells (TREMs) are a family of cell-surface receptors expressed broadly on myeloid cells. The first TREM identified, TREM1, was characterized as an...

2024年12月25日 · TREM1 (Triggering Receptor Expressed On Myeloid Cells 1) is a Protein Coding gene. Diseases associated with TREM1 include Maxillary Sinusitis and Pneumonia. Among its related pathways are Innate Immune System and Toll-like receptor signaling pathway.

Triggering receptors expressed on myeloid cells (TREMs) are a family of cell-surface receptors expressed broadly on myeloid cells. The first TREM identified, TREM1, was characterized as an amplifier of the immune response that potentiates granulocyte and monocyte responses to microbial products 1.

TREM1 signaling pathway. TREM1, a member of the immunoglobulin superfamily, lacks any signaling motif in its intracytoplasmic domain due to its specific structural characteristics; therefore, its signaling relies on binding with DAP12 [].The transmembrane lysine residue of TREM1, which carries a positive charge, interacts with the negatively charged aspartic acid …

TREM-1 is an important signaling receptor expressed on neutrophils and monocytes that plays an important role in systemic infections. Here, we review the intracellular signaling pathways that mediate the immunological effects of TREM-1.

Triggering receptor expressed on myeloid cells 1 (TREM1) is a cell surface receptor expressed on neutrophils, monocytes and some tissue macrophages, where it functions as an immunoregulator that controls myeloid cell responses.

Triggering receptor expressed on myeloid cells 1 (TREM-1) plays a pivotal role in human health and disease (1 – 6). Despite promising preclinical data and safety in humans, the first clinical inhibitor of TREM-1 (peptide LR12 or nangibotide) failed to reach significance for the primary endpoint in ASTONISH phase IIb sepsis trial (7, 8).

2024年3月27日 · In vitro, Trem1 -deficient microglia are resistant to amyloid-β 42 oligomer-induced bioenergetic changes, suggesting that amyloid-β 42 oligomer stimulation disrupts homeostatic microglial...

2019年7月1日 · Here we demonstrate that peripheral CD11b + CD45 + myeloid cells magnify stroke injury via activation of triggering receptor expressed on myeloid cells 1 (TREM1), an amplifier of proinflammatory...